跨物种PET成像显示PTSD杏仁核HDAC6抑制证据
该转化研究使用新型HDAC6选择性PET示踪剂[18F]Bavarostat,在人类中发现PTSD患者杏仁核HDAC6可用性显著低于非创伤暴露对照,并在啮齿类单次延长应激模型中通过病例对照和纵向分析验证了HDAC6可用性降低,提示HDAC6可能参与PTSD病理生理。
要点
- PTSD患者杏仁核HDAC6可用性显著低于非创伤暴露对照。
- 啮齿类单次延长应激模型支持HDAC6可用性降低。
- HDAC6可能成为PTSD新型药理靶点。
核心结论
- 跨物种PET成像证据提示HDAC6抑制与PTSD病理生理相关。
研究设计与样本
- 转化性正电子发射断层扫描脑成像研究,使用HDAC6选择性示踪剂[18F]Bavarostat。
- 人类为PTSD患者与非创伤暴露对照比较,啮齿类采用单次延长应激模型进行病例对照与个体内纵向分析。
主要发现
- 人类PTSD患者杏仁核HDAC6可用性显著低于非创伤暴露对照。
- 啮齿类单次延长应激模型中HDAC6可用性降低,病例对照与纵向分析均支持。
临床怎么用
- 提示HDAC6可作为PTSD潜在药理靶点,但尚需进一步临床验证。
局限性
- 原文未报告样本量、效应值及统计细节,证据为概念验证性质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Histone deacetylases (HDACs), typically known for regulating gene expression, also play a major role in protein regulation outside of histone modification. Emerging evidence suggests the HDACs may be novel pharmacologic targets in complex disorders such as posttraumatic stress disorder (PTSD). Histone deacetylase 6 (HDAC6) regulates microtubule function and plays a role in stress-related cortisol signaling in serotonergic regions of the brain by maintaining the nuclear translocation of glucocorticoid receptors. Here, we report results of a translational positron emission tomography brain imaging study using a novel HDAC6-selective radiotracer, [18F]Bavarostat. In humans, we demonstrate significantly lower availability of HDAC6 in the amygdala of individuals with PTSD compared to non-trauma exposed controls. These proof-of-concept human findings are supported by rodent findings of reduced HDAC6 availability both in case-control groups and within-subject longitudinal analysis using a single prolonged stress model. Together, our translational findings demonstrate a potential role for HDAC6 in the pathophysiology of PTSD.
引用
- Bonomi RE, Naganawa M, McRiley D, et al. PET imaging evidence of HDAC6 suppression in the amygdala across species in PTSD. Mol Psychiatry. 2025. PMID: 40753309. doi:10.1038/s41380-025-03124-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。